Benchmark analyst Raymond Myers raised his price target for Exact Sciences (EXAS) to $50 from $34 after UnitedHealth (UNH) said last night that it will cover Cologuard at the recommended three-year interval, beginning on July 1. Exact in premarket trading is up 9%, or $2.92, to $35.57. Coverage from UnitedHealth, the last of the major payor holdouts, "cements Cologuard as standard of care" for colon cancer screening, Myers tells investors in a research note. He has a Buy rating on the shares.
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Biohaven Pharmaceutical... To see the rest of the story go to thefly.com. See Story Here
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here